Tb and hiv co infection full details for md exams 15marks with dosage
Reading Document
Medical Text Search
TB HIV co-infection epidemiology pathogenesis diagnosis management
Medical Text Search
TB HIV co-infection ART antiretroviral therapy timing dosage drug interactions IRIS
GradeResponse
GradeResponse
I have solid retrieval. Now compiling the full comprehensive answer from retrieved sources plus my own knowledge.
TB-HIV Co-infection — Complete Review for MD Examinations (15 Marks)
1. INTRODUCTION & EPIDEMIOLOGY
TB-HIV co-infection represents one of the most lethal synergistic interactions in infectious disease. Each disease accelerates the other's progression:
- TB is the leading cause of death in HIV-infected individuals worldwide
- ~10 million new TB cases/year globally; ~8–11% are HIV co-infected
- HIV-infected individuals have a 20–30× higher lifetime risk of developing active TB compared to HIV-negative persons
- India, South Africa, and Sub-Saharan Africa carry the highest burden
- "Deadly duo" — TB accounts for ~25–30% of AIDS-related deaths
2. PATHOGENESIS — WHY THEY POTENTIATE EACH OTHER
TB → worsens HIV
| Mechanism | Effect |
|---|---|
| TB causes immune activation | Upregulates HIV replication (TNF-α, IL-6) |
| Mycobacterial antigens activate CD4+ T cells | HIV preferentially infects activated CD4+ cells |
| TB accelerates CD4 decline | Rapid progression to AIDS |
HIV → worsens TB
| Mechanism | Effect |
|---|---|
| CD4 depletion (<200 cells/µL) | Loss of granuloma integrity → dissemination |
| Impaired macrophage activation | Failure to contain M. tuberculosis |
| Reduced IFN-γ, TNF-α production | Defective delayed hypersensitivity |
| Th1 → Th2 shift | Impaired cell-mediated immunity |
Key point: HIV primarily impairs the CD4+ Th1 response, which is the cornerstone of anti-TB immunity.
3. CLINICAL FEATURES
CD4-Dependent Presentation
| CD4 Count | TB Presentation |
|---|---|
| >350 cells/µL | Typical: upper lobe cavitary disease, AFB smear positive |
| 200–350 cells/µL | Mixed/atypical features |
| <200 cells/µL | Atypical: lower/middle lobe, no cavitation, smear-negative, disseminated, extrapulmonary |
| <50 cells/µL | Miliary TB, bacteremia, absent tuberculin reaction ("anergy") |
Classic Symptoms
- Pulmonary: chronic cough >2 weeks, hemoptysis, dyspnea, night sweats, weight loss, fever
- Extrapulmonary (more common with low CD4):
- Lymphadenopathy (most common extrapulmonary site in HIV)
- TB meningitis (headache, neck rigidity, CN palsies)
- TB pericarditis (Beck's triad, friction rub)
- Miliary TB (hepatosplenomegaly, choroid tubercles on fundoscopy)
- Abdominal TB, skeletal TB (Pott's disease)
- TB peritonitis
High-yield: In HIV, TB is extrapulmonary or disseminated in ~50% of cases vs. ~15% in immunocompetent patients.
4. DIAGNOSIS
WHO "Universal Testing" Rule
WHO and CDC both recommend routine HIV testing for ALL patients diagnosed with TB, given the increased risk, and vice versa (OI Guidelines, p. 360).
Step-by-step Diagnostic Approach
A. For TB in HIV patient:
| Test | Details |
|---|---|
| Sputum AFB smear | Sensitivity ↓ in HIV (~40–50%), negative does not rule out |
| Sputum culture (LJ/BACTEC) | Gold standard; results in 2–8 weeks |
| GeneXpert MTB/RIF (CBNAAT) | Preferred — rapid (2 hrs), detects RIF resistance, WHO recommended even in HIV |
| Chest X-ray | Atypical in HIV; lower lobe, miliary, pleural effusion, mediastinal adenopathy, no cavities at low CD4 |
| Tuberculin Skin Test (TST) | Often false negative in HIV (<5mm may still be positive); ≥5mm = positive in HIV |
| IGRA (QuantiFERON-TB Gold) | Better than TST but unreliable when CD4 <100 |
| BAL / bronchoscopy | For sputum-scarce/smear-negative cases |
| FNAC / biopsy of lymph nodes | For lymphadenopathy — granulomas, AFB |
| CSF, pleural, pericardial fluid analysis | For extrapulmonary sites |
| Blood culture (BACTEC) | For disseminated/miliary TB in severe immunosuppression |
| Urine LAM (lipoarabinomannan) | Lateral flow assay — WHO recommends for HIV+ with CD4 <100 or seriously ill |
B. For HIV in TB patient:
- ELISA (4th gen) → confirm with Western Blot or line immunoassay
- CD4 count — guides ART initiation timing
- HIV viral load — baseline and monitoring
5. TREATMENT — THE CORNERSTONE
PHASE 1: TREAT TB FIRST
Anti-TB treatment is initiated first, then ART is added (not simultaneously — to reduce pill burden, side effects, IRIS risk, and drug interactions).
Anti-TB Regimen (Standard RNTCP/WHO)
2HRZE / 4HR (same as HIV-negative patients)
| Drug | Dose | Duration |
|---|---|---|
| Isoniazid (H) | 5 mg/kg/day (max 300 mg/day) | 6 months |
| Rifampicin (R) | 10 mg/kg/day (max 600 mg/day) | 6 months |
| Pyrazinamide (Z) | 25 mg/kg/day (max 2 g/day) | 2 months (intensive phase) |
| Ethambutol (E) | 15–20 mg/kg/day (max 1.6 g/day) | 2 months (intensive phase) |
Pyridoxine (Vitamin B6): 25–50 mg/day — mandatory in all HIV-TB co-infected patients (INH + HIV neuropathy risk is additive).
Extended regimen: TB meningitis or bone TB → extend to 9–12 months (2HRZE/7HR).
PHASE 2: WHEN TO START ART
This is the most important and exam-favorite question:
| CD4 Count | Timing of ART Initiation |
|---|---|
| CD4 < 50 cells/µL | Start ART within 2 weeks of starting TB treatment |
| CD4 50–200 cells/µL | Start ART within 2–4 weeks |
| CD4 > 200 cells/µL | Start ART within 8–12 weeks (after 2 months intensive phase) |
| TB meningitis | Delay ART to 4–8 weeks (higher IRIS risk in CNS — fatal paradoxical worsening) |
Rationale for not starting simultaneously: Overlapping toxicities (hepatotoxicity, peripheral neuropathy), high pill burden, adherence difficulty, IRIS risk, drug interactions with rifampicin.
PREFERRED ART REGIMEN IN TB-HIV CO-INFECTION
(OI Guidelines in Adults/Adolescents, p. 490)
First-Line Preferred (AI Evidence):
Dolutegravir (DTG) + 2 NRTIs
| Drug | Standard Dose | Dose with Rifampicin |
|---|---|---|
| Dolutegravir (DTG) | 50 mg once daily | 50 mg TWICE daily (rifampicin induces UGT1A1 and CYP3A4) |
| Tenofovir DF (TDF) | 300 mg once daily | No change |
| Lamivudine (3TC) or Emtricitabine (FTC) | 3TC: 300 mg OD / FTC: 200 mg OD | No change |
| Abacavir (ABC) | 600 mg once daily | No change |
| Tenofovir AF (TAF) | 25 mg once daily | Avoid with rifampicin (levels ↓↓) |
DTG dose doubling is critical: Rifampicin reduces DTG levels by ~50–75% due to strong CYP/UGT induction — dose must be doubled to 50 mg BD when co-administered with rifampicin.
Alternative Regimens:
| ART Drug | Interaction with Rifampicin | Dose Adjustment |
|---|---|---|
| Efavirenz (EFV) | Moderate CYP3A4 induction | No change (600 mg HS) or 800 mg if >60 kg (debated) |
| Raltegravir (RAL) | Rifampicin ↓ levels by 40–60% | Double dose: 800 mg BD |
| Lopinavir/ritonavir (LPV/r) | Rifampicin dramatically ↓ LPV levels | NOT recommended (or double-boosted regimen — complex) |
| Nevirapine (NVP) | Rifampicin ↓ levels significantly | Avoid — inadequate levels, hepatotoxicity |
| Atazanavir/ritonavir | Significant ↓ levels | Avoid with rifampicin |
| Rilpivirine | Severely ↓ levels | Contraindicated with rifampicin |
| Elvitegravir/cobicistat | Cobicistat is CYP3A4 inhibitor — rifampicin renders it ineffective | Contraindicated |
If PI-based regimen needed: Replace rifampicin with Rifabutin 150 mg OD (weaker CYP3A4 inducer). Adjust LPV/r to 400/400 mg BD.
6. DRUG-DRUG INTERACTIONS — RIFAMPICIN AND ART
This is a 15-mark exam mainstay:
| Rifampicin Effect | Mechanism | Clinical Impact |
|---|---|---|
| Strong CYP3A4 inducer | ↑ hepatic metabolism | ↓ plasma levels of PIs, NNRTIs, INSTIs |
| UGT1A1 inducer | ↑ glucuronidation | ↓ DTG, RAL levels |
| P-glycoprotein inducer | ↑ drug efflux | ↓ absorption of several ARTs |
Solution: Use Rifabutin (instead of Rifampicin) if PI-based ART is mandatory:
- Rifabutin 150 mg OD (with ritonavir-boosted PI)
- Rifabutin does NOT significantly induce CYP3A4 at low doses when boosted
7. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS)
Definition
Paradoxical worsening of TB symptoms or new inflammatory manifestations after initiating ART due to restored immune response.
Types
| Type | Description |
|---|---|
| Paradoxical IRIS | Worsening of known TB after ART start; most common form |
| Unmasking IRIS | Subclinical/undiagnosed TB becomes apparent after ART |
Risk Factors for IRIS
- CD4 < 50 cells/µL at ART start
- High baseline HIV viral load
- Short interval between TB treatment and ART initiation
- Disseminated or extrapulmonary TB
- Rapid CD4 rise after ART
Clinical Features
- Fever, lymphadenopathy, worsening pulmonary infiltrates
- Expanding CNS lesions (most dangerous — tuberculomas)
- New pleural/pericardial effusions
- Paradoxical deterioration despite microbiological improvement
Management of IRIS
- Do NOT stop ART (most important)
- Do NOT stop anti-TB therapy
- Mild-moderate IRIS: NSAIDs (ibuprofen 400 mg TDS)
- Severe IRIS: Prednisolone 1.5 mg/kg/day × 2 weeks, then taper (evidence from CAPE trial — reduces hospitalization)
- CNS IRIS: Higher-dose corticosteroids, consider hospitalization
- Drainage of fluctuant lymph nodes if needed
8. LATENT TB INFECTION (LTBI) IN HIV — ISONIAZID PREVENTIVE THERAPY (IPT)
| Parameter | Details |
|---|---|
| Indication | All HIV+ patients with positive TST (≥5 mm) or IGRA AND no active TB |
| Drug | Isoniazid 300 mg OD |
| Duration | 6 months (WHO); 36 months (some guidelines in high-burden settings) |
| Co-administer | Pyridoxine 25–50 mg/day |
| WHO 3I strategy | Intensified Case Finding + Isoniazid Preventive Therapy + Infection Control |
| TB/HIV Preventive Therapy (TPT) | WHO 2020: Preferred regimen 3HP (weekly INH 900mg + Rifapentine 900mg × 12 doses) or 1HP (daily × 28 days) |
Contraindication to IPT: Active TB must be ruled out before starting (GeneXpert, CXR, symptoms).
9. DRUG TOXICITIES — OVERLAPPING IN TB-HIV
| Toxicity | Anti-TB Drugs | ART Drugs |
|---|---|---|
| Hepatotoxicity | INH, RIF, PZA | Nevirapine, PIs, efavirenz |
| Peripheral neuropathy | Isoniazid | Stavudine (d4T), ddI, AZT |
| Rash/Stevens-Johnson | Pyrazinamide, INH | Nevirapine, abacavir (HLA-B*5701) |
| Nephrotoxicity | Streptomycin, aminoglycosides | Tenofovir (TDF) |
| GI toxicity | All | All |
| CNS effects | INH (seizures) | Efavirenz (vivid dreams, psychosis) |
10. SPECIAL SITUATIONS
A. TB Meningitis in HIV
- Use dexamethasone (not prednisolone) 0.4 mg/kg/day × 4 weeks then taper
- Delay ART to 4–8 weeks (paradoxical IRIS in CNS is life-threatening)
- Extended TB treatment: 9–12 months
B. Pregnancy with TB-HIV
- Anti-TB drugs safe in pregnancy (avoid Streptomycin — ototoxicity)
- ART: DTG preferred (monitor neural tube defects risk — data reassuring)
- Efavirenz 600 mg — safe in pregnancy (WHO 2016)
- Pyridoxine mandatory
C. TB in Children with HIV
- WHO and guidelines recommend universal HIV testing in all TB-diagnosed children
- Dosing is weight-based
- ART timing same as adults based on CD4%
D. MDR-TB in HIV
- Treatment: Bedaquiline + Pretomanid + Linezolid (BPaL) or longer regimens
- QTc prolongation — monitor ECG (bedaquiline + some ARTs both prolong QTc)
- ART: avoid drugs that prolong QTc; DTG preferred
11. MONITORING PARAMETERS
| Parameter | Frequency |
|---|---|
| CD4 count | Baseline, then every 3–6 months |
| HIV viral load | Baseline, 6 months, then annually |
| LFTs (AST/ALT/bilirubin) | Baseline, at 2 weeks, monthly for 2 months |
| Renal function (Cr, eGFR) | Baseline, monthly if on TDF |
| CBC | Baseline and as needed |
| Sputum AFB/culture | At 2, 5, 6 months of TB treatment |
| Ophthalmology | Baseline if on ethambutol |
| Weight | Monthly |
12. KEY HIGH-YIELD EXAM POINTS — SUMMARY TABLE
| Topic | High-Yield Fact |
|---|---|
| Most common OI in HIV | Tuberculosis (globally) |
| Most common extrapulmonary site | Lymph nodes |
| TB risk in HIV | 20–30× increased |
| ART drug of choice | DTG-based regimen |
| DTG dose with rifampicin | 50 mg BD (double the dose) |
| Avoid with rifampicin | Rilpivirine, cobicistat/elvitegravir, NVP, most PIs |
| ART timing: CD4 <50 | Within 2 weeks |
| Exception to early ART | TB meningitis — delay 4–8 weeks |
| IRIS treatment | Prednisolone 1.5 mg/kg/day |
| LTBI prevention | INH 300 mg OD × 6 months + B6 |
| Urine LAM — when? | HIV+ with CD4 <100 or seriously ill |
| IPT contraindication | Active TB not ruled out |
| Mandatory supplement | Pyridoxine 25–50 mg/day |
| TST cutoff in HIV | ≥5 mm (not the usual 10/15 mm) |
13. WHO "3I" STRATEGY FOR TB-HIV
- Intensified Case Finding (ICF) — Screen all HIV patients for TB at every visit using 4-symptom screen (cough, fever, weight loss, night sweats)
- Isoniazid Preventive Therapy (IPT) — For all LTBI-positive HIV patients
- Infection Control — TB infection control measures in HIV care settings
QUICK DOSAGE REFERENCE CARD
| Drug | Dose | Key Note |
|---|---|---|
| Isoniazid | 5 mg/kg/day (max 300 mg) | + Pyridoxine always |
| Rifampicin | 10 mg/kg/day (max 600 mg) | Major drug interactions |
| Pyrazinamide | 25 mg/kg/day (max 2 g) | Intensive phase only |
| Ethambutol | 15–20 mg/kg/day (max 1.6 g) | Monitor vision |
| Pyridoxine (B6) | 25–50 mg/day | Mandatory in HIV-TB |
| Dolutegravir | 50 mg OD → 50 mg BD with RIF | Double dose with rifampicin |
| Efavirenz | 600 mg HS | Alternative to DTG |
| Raltegravir | 400 mg BD → 800 mg BD with RIF | Double dose with rifampicin |
| Tenofovir DF | 300 mg OD | Monitor renal function |
| Lamivudine | 300 mg OD | Backbone NRTI |
| Prednisolone (IRIS) | 1.5 mg/kg/day × 2 weeks, taper | For severe IRIS |
| Dexamethasone (TBM) | 0.4 mg/kg/day × 4 weeks, taper | TB meningitis |
| Rifabutin (PI-based ART) | 150 mg OD | Alternative to rifampicin |
| INH (LTBI/IPT) | 300 mg OD × 6 months | + Pyridoxine |
Sources: Prevention and Treatment of Opportunistic Infections in Adults/Adolescents and Children with HIV (OI Guidelines, pp. 360, 490); WHO TB/HIV Guidelines 2022; Harrison's Principles of Internal Medicine; National TB Elimination Programme (NTEP) Guidelines.
This is a shared conversation. Sign in to Orris to start your own chat.